310 related articles for article (PubMed ID: 26284424)
1. The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β.
Rondeau JM; Ramage P; Zurini M; Gram H
MAbs; 2015; 7(6):1151-60. PubMed ID: 26284424
[TBL] [Abstract][Full Text] [Related]
2. One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1β.
Blech M; Peter D; Fischer P; Bauer MM; Hafner M; Zeeb M; Nar H
J Mol Biol; 2013 Jan; 425(1):94-111. PubMed ID: 23041424
[TBL] [Abstract][Full Text] [Related]
3. Structure-based Development of Human Interleukin-1β-Specific Antibody That Simultaneously Inhibits Binding to Both IL-1RI and IL-1RAcP.
Kuo WC; Lee CC; Chang YW; Pang W; Chen HS; Hou SC; Lo SY; Yang AS; Wang AH
J Mol Biol; 2021 Feb; 433(4):166766. PubMed ID: 33359099
[TBL] [Abstract][Full Text] [Related]
4. A novel human anti-interleukin-1β neutralizing monoclonal antibody showing in vivo efficacy.
Goh AX; Bertin-Maghit S; Ping Yeo S; Ho AW; Derks H; Mortellaro A; Wang CI
MAbs; 2014; 6(3):765-73. PubMed ID: 24671001
[TBL] [Abstract][Full Text] [Related]
5. Selective activation of pro-anti-IL-1β antibody enhances specificity for autoinflammatory disorder therapy.
Lin WW; Lu YC; Huang BC; Chuang CH; Cheng YA; Chen IJ; Liu HJ; Ho KW; Liao TY; Liu ES; Wu TY; Chang LS; Hong ST; Cheng TL
Sci Rep; 2021 Jul; 11(1):14846. PubMed ID: 34290297
[TBL] [Abstract][Full Text] [Related]
6. Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes.
Church LD; McDermott MF
Expert Rev Clin Immunol; 2010 Nov; 6(6):831-41. PubMed ID: 20979548
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody.
Chakraborty A; Tannenbaum S; Rordorf C; Lowe PJ; Floch D; Gram H; Roy S
Clin Pharmacokinet; 2012 Jun; 51(6):e1-18. PubMed ID: 22550964
[TBL] [Abstract][Full Text] [Related]
8. XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases.
Owyang AM; Issafras H; Corbin J; Ahluwalia K; Larsen P; Pongo E; Handa M; Horwitz AH; Roell MK; Haak-Frendscho M; Masat L
MAbs; 2011; 3(1):49-60. PubMed ID: 21048425
[TBL] [Abstract][Full Text] [Related]
9. Canakinumab for the treatment of active systemic juvenile idiopathic arthritis.
Orrock JE; Ilowite NT
Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1015-24. PubMed ID: 27367267
[TBL] [Abstract][Full Text] [Related]
10. Structure and function of chicken interleukin-1 beta mutants: uncoupling of receptor binding and in vivo biological activity.
Chen WT; Huang WY; Chen T; Salawu EO; Wang D; Lee YZ; Chang YY; Yang LW; Sue SC; Wang X; Yin HS
Sci Rep; 2016 Jun; 6():27729. PubMed ID: 27278931
[TBL] [Abstract][Full Text] [Related]
11. Antibodies to domains II and III of the IL-1 receptor accessory protein inhibit IL-1 beta activity but not binding: regulation of IL-1 responses is via type I receptor, not the accessory protein.
Yoon DY; Dinarello CA
J Immunol; 1998 Apr; 160(7):3170-9. PubMed ID: 9531272
[TBL] [Abstract][Full Text] [Related]
12. Structure of IL-17A in complex with a potent, fully human neutralizing antibody.
Gerhardt S; Abbott WM; Hargreaves D; Pauptit RA; Davies RA; Needham MR; Langham C; Barker W; Aziz A; Snow MJ; Dawson S; Welsh F; Wilkinson T; Vaugan T; Beste G; Bishop S; Popovic B; Rees G; Sleeman M; Tuske SJ; Coales SJ; Hamuro Y; Russell C
J Mol Biol; 2009 Dec; 394(5):905-21. PubMed ID: 19835883
[TBL] [Abstract][Full Text] [Related]
13. Structural insights into the assembly and activation of IL-1β with its receptors.
Wang D; Zhang S; Li L; Liu X; Mei K; Wang X
Nat Immunol; 2010 Oct; 11(10):905-11. PubMed ID: 20802483
[TBL] [Abstract][Full Text] [Related]
14. Treating inflammation by blocking interleukin-1 in humans.
Dinarello CA; van der Meer JW
Semin Immunol; 2013 Dec; 25(6):469-84. PubMed ID: 24275598
[TBL] [Abstract][Full Text] [Related]
15. Canakinumab: a review of its use in the management of systemic juvenile idiopathic arthritis.
Hoy SM
BioDrugs; 2015 Apr; 29(2):133-42. PubMed ID: 25822149
[TBL] [Abstract][Full Text] [Related]
16. Production of a human neutralizing monoclonal antibody and its crystal structure in complex with ectodomain 3 of the interleukin-13 receptor α1.
Redpath NT; Xu Y; Wilson NJ; Fabri LJ; Baca M; Andrews AE; Braley H; Lu P; Ireland C; Ernst RE; Woods A; Forrest G; An Z; Zaller DM; Strohl WR; Luo CS; Czabotar PE; Garrett TP; Hilton DJ; Nash AD; Zhang JG; Nicola NA
Biochem J; 2013 Apr; 451(2):165-75. PubMed ID: 23384096
[TBL] [Abstract][Full Text] [Related]
17. Canakinumab for the treatment of systemic juvenile idiopathic arthritis.
Grom AA
Expert Rev Clin Immunol; 2014 Nov; 10(11):1427-35. PubMed ID: 25269376
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis.
Sun H; Van LM; Floch D; Jiang X; Klein UR; Abrams K; Sunkara G
J Clin Pharmacol; 2016 Dec; 56(12):1516-1527. PubMed ID: 27119439
[TBL] [Abstract][Full Text] [Related]
19. [Canakinumab: a promising treatment in rheumatology].
Fabreguet I; So A
Rev Med Suisse; 2012 Jan; 8(323):57-60. PubMed ID: 22303742
[TBL] [Abstract][Full Text] [Related]
20. Unusual water-mediated antigenic recognition of the proinflammatory cytokine interleukin-18.
Argiriadi MA; Xiang T; Wu C; Ghayur T; Borhani DW
J Biol Chem; 2009 Sep; 284(36):24478-89. PubMed ID: 19553661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
